VIR-5500 Shrinks Prostate Tumors, Offers Hope
Adelaide News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
VIR-5500, a new immunotherapy drug, shows remarkable results in treating advanced prostate cancer. In phase one trials, it shrank tumors and significantly reduced cancer markers in some patients. The drug, developed by Vir Biotechnology, targets men whose cancer no longer responds to standard treatments. It works by linking the bodys killer T-cells directly to tumor cells, reducing side effects. In the trial, eighty-eight percent of patients reported only mild side effects, and one patients liver tumors vanished completely. Experts and groups like Prostate Cancer UK are optimistic about larger trials to confirm the potential for longer lives and cures.
Support the show
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected]
View sources & latest updates
https://sources.thednn.ai/47a19b257174dc9b